Home Drug Guide Abrocitinib

Drug Guide

Generic Name

Abrocitinib

Brand Names Cibinqo

Classification

Therapeutic: Antirheumatic

Pharmacological: Janus kinase (JAK) inhibitor

FDA Approved Indications

Atopic dermatitis (moderate to severe) in adults

Mechanism of Action

Abrocitinib selectively inhibits Janus kinase 1 (JAK1), disrupting the JAK-STAT signaling pathway involved in inflammatory and immune responses, thereby reducing inflammation associated with atopic dermatitis.

Dosage and Administration

Adult: 100 mg orally once daily, may increase to 200 mg based on response and tolerability.

Pediatric: Not approved for pediatric use.

Geriatric: No specific dosage adjustment necessary but monitor for increased risk of adverse effects in elderly.

Renal Impairment: Use with caution; no specific adjustment recommended.

Hepatic Impairment: Use with caution; no specific adjustment recommended.

Pharmacokinetics

Absorption: Rapidly absorbed with peak plasma concentrations in approximately 1-2 hours.

Distribution: Extensive protein binding (~99%).

Metabolism: Primarily hepatic via CYP2C19 and CYP3A4 enzymes.

Excretion: Metabolites excreted mainly in urine and feces.

Half Life: Approximately 4 hours.

Contraindications

Hypersensitivity to abrocitinib or any component of the formulation.

Precautions

Increased risk of infections, including serious infections; monitoring required.
Potential for blood dyscrasias; regular blood count monitoring recommended.
Not recommended for use during pregnancy; consult guidelines for contraception.

Adverse Reactions - Common

Nausea (Unknown)
Acne (Unknown)
Headache (Unknown)

Adverse Reactions - Serious

Serious infections (e.g., pneumonia, herpes zoster) (Rare)
Blood clots (Rare)
Liver injury (Rare)

Drug-Drug Interactions

CYP3A4 inducers or inhibitors (e.g., rifampin, ketoconazole) may alter abrocitinib levels.

Drug-Food Interactions

N/A

Drug-Herb Interactions

N/A

Nursing Implications

Assessment: Monitor for signs of infection, blood dyscrasias, and liver function abnormalities.

Diagnoses:

Risk for infection related to immune suppression.
Impaired skin integrity related to disease and adverse effects.

Implementation: Monitor laboratory values regularly; educate patient on infection precautions.

Evaluation: Evaluate efficacy by reduction in dermatitis severity; monitor adverse effects.

Patient/Family Teaching

Report signs of infection immediately.
Follow dosing instructions carefully.
Avoid live vaccines during therapy.
Inform about possible side effects and when to seek medical attention.

Special Considerations

Black Box Warnings:

Serious infections, Malignancies, Thrombosis

Genetic Factors: None specified.

Lab Test Interference: May affect liver enzymes and blood counts.

Overdose Management

Signs/Symptoms: Potential severe immunosuppression, liver injury, or bleeding.

Treatment: Supportive care; no specific antidote. Immediate medical attention required.

Storage and Handling

Storage: Store at room temperature away from light and moisture.

Stability: Stable through expiration date on the package.